Skip to Content

'
Linus Ho, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1991 Stanford University School of Medicine, Stanford, CA, MD, Medicine
1991 Stanford University School of Medicine, Stanford, CA, PHD, Cancer biology
1983 University of Texas, Austin, TX, BA, summa cum laude, Zoology
1983 University of Texas, Austin, TX, BS, summa cum laude, Chemistry

Experience/Service

Other Appointments/Responsibilities

Research Fellow, Harvard Medical School, Dept. of Biological Chemistry and Molecular Pharmacology, Boston, MA, 1/1996-3/1999

Institutional Committee Activities

Member, faculty senate ad hoc research affairs committee, 1/2002-1/2003
Member, IRG review committee for basic research projects, 1/2002

Selected Publications

Peer-Reviewed Original Research Articles

1. Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, Ho L, Ajani J, Phan A. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer 116(6):1446-53, 3/15/2010. PMID: 20108336.
2. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerkel GA, Lee JH, Ross WA, Tamm EP, Bhosale PR, Krishnan S, Das P, Ho L, Xiong H, Abbruzzese JL, Evans DB. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26(21):3487-95, 7/2008. PMID: 18640929.
3. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26(21):3496-502, 7/2008. PMID: 18640930.
4. Agarwal B, Correa AM, Ho L. Survival in pancreatic carcinoma based on tumor size. Pancreas 36(1):e15-20, 1/2008. PMID: 18192868.
5. Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, Madoff DC, Chang DZ, Ho L, Kopetz S, Wei SH, Curley SA, Abdalla EK. Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. J Gastrointest Surg 11(11):1498-504; discussion 1504-5, 11/2007. PMID: 17849166.
6. Reyes-Gibby CC, Chan W, Abbruzzese JL, Xiong HQ, Ho L, Evans DB, Varadhachary G, Bhat S, Wolff RA, Crane C. Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. J Pain Symptom Manage 34(3):244-52, 9/2007. PMID: 17513082.
7. Cao D, Zhang Q, Wu LS, Salaria SN, Winter JW, Hruban RH, Goggins MS, Abbruzzese JL, Maitra A, Ho L. Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases. Mod Pathol 20(5):570-8, 5/2007. PMID: 17396143.
8. Kouvaraki MA, Korapati AL, Rassidakis GZ, Tian L, Zhang Q, Chiao P, Ho L, Evans DB, Claret FX. Potential Role of Jun Activation Domain-Binding Protein 1 as a Negative Regulator of p27kip1 in Pancreatic Adenocarcinoma. Cancer Res 66:8581-9, 9/2006. PMID: 16951171.
9. Ajani JA, Jiang Y, Faust J, Chang BB, Ho L, Yao JC, Rousey S, Dakhil S, Cherny RC, Craig C, Bleyer A. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs 24(4):353-7, 7/2006. PMID: 16683077.
10. Ajani JA, Randolph Hecht J, Ho L, Baker J, Oortgiesen M, Eduljee A, Michaeli D. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer 106(9):1908-16, 5/2006. PMID: 16568451.
11. Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O'Reilly M, Lee JE, Wolff RA. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24(7):1145-51, 3/2006. PMID: 16505434.

Abstracts

1. Varadhachary GR, Wolff RA, Crane CH, Lee JE, Abdalla EK, Lee JH, Pisters PW, Ho L, Abbruzzese JL, Evans DB. Preoperative gemcitabine (gem) and bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma. Proc. Am. Soc. Clin. Oncol. 26 (#4630), 1/2008.
2. Ho L, Phan AT, Jhamb J, Mani M, Tetzlaff E, Lin E, Ajani JA, Abbruzzese JL, Overman MJ. Retrospective review of docetaxel, cisplatin and 5-FU (DCF) given on a weekly basis for the treatment of advanced gastric or esophageal cancer. Proc. Am. Soc. Clin. Oncol. 26 (#15525), 1/2008.
3. Ajani JA, Phan A, Ho L, Tetzlaff ED, Baker J, Wei Q. Phase I/II trial of docetaxel plus oxaliplatin and 5-fluorouracil (D-FOX) in patients with untreated, advanced gastric or gastroesophageal cancer. Proc. Am. Soc. Clin Oncol. 25 (#4612), 1/2007.
4. Votanopoulos K, Atwell C, Kouvaraki MA, Ciao P, Leyentaki V, Ho L, Evans DB, Rassidakis GZ. cFLIP overexpression protects tumor cells from Fas-induced apoptosis in pancreatic adenocarcinoma. Ann Surg Oncol 13(2):93-94, 2007.
5. Chun YS, Vauthey JN, Ribero D, Donadon M, Eng C, Brown TD, Chang DZ, Ho L, Curley SA, Abdalla EK. Systemic chemotherapy and two-stage hepatectomy in patients with extensive bilobar colorectal liver metastases: perioperative safety and survival. Gatroenterol 132(4):A838-A839, 2007.
6. Rana V, Krishnan S, Abbruzzese JL, Xiong HQ, Varadhachary GR, Ho L, Janjan NA, Evans DB, Wolff RA, Crane CH. Neoadjuvant chemotherapy improves outcomes of chemoradiation therapy for locally advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 24 (#4036), 1/2006.
7. Crane CH, Krishnan S, Rana V, Xiong HQ, Varadhachary G, Palla S, Evans DB, Das P, Ho L, Wolff RA. Does the addition of becacizumab to chemoradiation prolong median survival in locally advanced pancreatic cancer patients?. Int J Rad Oncol Biol Phys 66(3):S173 (#1076), 2006.

Last updated: 8/6/2013